0001209191-14-020605.txt : 20140314
0001209191-14-020605.hdr.sgml : 20140314
20140314154609
ACCESSION NUMBER: 0001209191-14-020605
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140312
FILED AS OF DATE: 20140314
DATE AS OF CHANGE: 20140314
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AQUINOX PHARMACEUTICALS, INC
CENTRAL INDEX KEY: 0001404644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 887 GREAT NORTHERN WAY
STREET 2: SUITE 450
CITY: VANCOUVER
STATE: A1
ZIP: V5T 4T5
BUSINESS PHONE: 604-629-9223
MAIL ADDRESS:
STREET 1: 887 GREAT NORTHERN WAY
STREET 2: SUITE 450
CITY: VANCOUVER
STATE: A1
ZIP: V5T 4T5
FORMER COMPANY:
FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS (USA) INC
DATE OF NAME CHANGE: 20070626
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ventures West 8 Limited Partnership
CENTRAL INDEX KEY: 0001599970
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36327
FILM NUMBER: 14694385
BUSINESS ADDRESS:
STREET 1: C/O FIVE CORNERS CAPITAL
STREET 2: 700 WEST GEORGIA STREET, SUITE 2500
CITY: VANCOUVER
STATE: A1
ZIP: V7Y 1B3
BUSINESS PHONE: 360-306-1224
MAIL ADDRESS:
STREET 1: C/O FIVE CORNERS CAPITAL
STREET 2: 700 WEST GEORGIA STREET, SUITE 2500
CITY: VANCOUVER
STATE: A1
ZIP: V7Y 1B3
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2014-03-12
0
0001404644
AQUINOX PHARMACEUTICALS, INC
AQXP
0001599970
Ventures West 8 Limited Partnership
C/O FIVE CORNERS CAPITAL
700 W. GEORGIA STREET, SUITE 2500
VANCOUVER
A1
V7Y 1B3
BRITISH COLUMBIA, CANADA
0
0
1
0
Common Special Voting Stock
2014-03-12
4
A
0
36502
0.00
A
40147
D
Common Special Voting Stock
2014-03-12
4
D
0
40147
0.00
D
0
D
Series A-1 Special Voting Stock
2014-03-12
4
D
0
284090
0.00
D
0
D
Series A-2 Special Voting Stock
2014-03-12
4
D
0
189393
0.00
D
0
D
Series B-1 Special Voting Stock
2014-03-12
4
D
0
326538
0.00
D
0
D
Series B-2 Special Voting Stock
2014-03-12
4
D
0
325035
0.00
D
0
D
Series C Special Voting Stock
2014-03-12
4
D
0
378786
0.00
D
0
D
Common Stock
2014-03-12
4
C
0
1543989
A
1543989
D
Common Exchangeable Shares
2014-03-12
4
A
0
36502
11.00
A
Common Stock
36502
40147
D
Common Exchangeable Shares
2014-03-12
4
C
0
40147
D
Common Stock
40147
0
D
Series A-1 Exchangeable Shares
2014-03-12
4
C
0
284090
D
Series A-1 Preferred Stock
284090
0
D
Series A-1 Preferred Stock
2014-03-12
4
C
0
284090
A
Common Stock
284090
0
D
Series A-1 Preferred Stock
2014-03-12
4
C
0
284090
D
Common Stock
284090
0
D
Series A-2 Exchangeable Shares
2014-03-12
4
C
0
189393
D
Series A-2 Preferred Stock
189393
0
D
Series A-2 Preferred Stock
2014-03-12
4
C
0
189393
A
Common Stock
189393
0
D
Series A-2 Preferred Stock
2014-03-12
4
C
0
189393
D
Common Stock
189393
0
D
Series B-1 Exchangeable Shares
2014-03-12
4
C
0
326538
D
Series B-1 Preferred Stock
326538
0
D
Series B-1 Preferred Stock
2014-03-12
4
C
0
326538
A
Common Stock
326538
0
D
Series B-1 Preferred Stock
2014-03-12
4
C
0
326538
D
Common Stock
326538
0
D
Series B-2 Exchangeable Shares
2014-03-12
4
C
0
325035
D
Series B-2 Preferred Stock
325035
0
D
Series B-2 Preferred Stock
2014-03-12
4
C
0
325035
A
Common Stock
325035
0
D
Series B-2 Preferred Stock
2014-03-12
4
C
0
325035
D
Common Stock
325035
0
D
Series C Exchangeable Shares
2014-03-12
4
C
0
378786
D
Series C Preferred Stock
378786
0
D
Series C Preferred Stock
2014-03-12
4
C
0
378786
A
Common Stock
378786
0
D
Series C Preferred Stock
2014-03-12
4
C
0
378786
D
Common Stock
378786
0
D
Five Corners Capital Inc., the general partner of Ventures West 8 Limited Partnership, has sole voting and investment power with respect to the shares held by Ventures West 8 Limited Partnership. The directors of Five Corners Capital Inc. are Dr. Gary Bridger and Kenneth Galbraith. Dr. Bridger and Kenneth Galbraith disclaim beneficial ownership of all shares except to the extent of their pecuniary interest.
Each share of the issuer's Common, Series A-1, Series A-2, Series B-1, Series B-2 and Series C Special Voting Stock was redeemed upon the closing of the issuer's initial public offering for $0.0000192 per share.
Each share of the issuer's Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and has no expiration date.
The Common Exchangeable Shares of Aquinox Pharmaceuticals Inc., a corporation under the Canadian Business Corporations Act ("AQXP Canada"), were exchanged for Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and have no expiration date.
The Series A-1, Series A-2, Series B-1, Series B-2 and Series C Exchangeable Shares of AQXP Canada were exchanged for Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock, respectively, of the issuer on a 1-to-1 basis immediately prior to the closing of the issuer's initial public offering, and have no expiration date.
/s/ Gary J. Bridger, Managing Director of Five Corners Capital Inc.
2014-03-14